December 4, 2014 — University of Oxford, in collaboration with Oxford University Hospitals NHS Trust, partners with ProNova Solutions to incorporate ProNova’s SC360 proton therapy system in Oxford University’s Precision Cancer Medicine Institute (PCMI).
The PCMI will be a clinical research facility for the development, testing and implementation of personalized, minimally invasive cancer treatments combined with molecularly targeted agents for diagnosis, imaging and therapy. Proton Therapy will play a key role in the focused research directed to improving curative treatments for patients with early-stage cancer where minimizing side effects has substantial personal, societal and economic benefits.
ProNova will equip the new proton center with three treatment rooms including two superconducting gantry treatment rooms and one fixed beam treatment room. Each treatment room will include Fast Scanning IMPT technology with integrated 3-D imaging. This unique solution merges leading edge pencil beam delivery with innovative imaging capability to aid physicians and therapists in minimizing collateral damage to healthy tissue and maximizing dose to the tumor.